Skip to content

Study · Non-randomized trial · 2019

4 results

Gonadotropin releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome.

Ozelci R, Dilbaz S, Dilbaz B, Cırık DA, Yılmaz S, Tekin OM

Taiwanese journal of obstetrics & gynecology1 Mar 2019Cited by 3 (Europe PMC)

PMID30910145 (opens in a new tab)DOI10.1016/j.tjog.2019.01.012 (opens in a new tab)PepBankPUB-30910145
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with PCOS undergoing IUI, adding cetrorelix to recombinant FSH significantly lowered LH versus recombinant FSH alone.

    In plain wordsIn women with PCOS undergoing IUI, adding cetrorelix lowered LH compared with recombinant FSH alone.

    Peptide
    Cetrorelix
    Outcome
    DecreaseLH on hCG administration day
    Study

    n: not reported in source

    Comparator
    Recombinant FSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    As expected, the mean value of luteinizing hormone and progesterone, on the day of human chorionic gonadotropin administration were statistically significantly lower in patients receiving GnRH antagonist than the control group (p = 0.002).
    2 context sentences
    Summary · context
    A total of 175 intrauterine insemination (IUI) cycles in women with polycystic ovary syndrome (PCOS) were included in the study.
    Summary · context
    Women in the control group (n = 87) underwent controlled ovarian stimulation (COS) with recombinant follicle stimulating hormone (r-FSH) only, while women in the study group (n = 88) were administered r-FSH plus cetrorelix.
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with PCOS undergoing IUI, adding cetrorelix to recombinant FSH significantly lowered progesterone versus recombinant FSH alone.

    In plain wordsIn women with PCOS undergoing IUI, adding cetrorelix lowered progesterone compared with recombinant FSH alone.

    Peptide
    Cetrorelix
    Outcome
    DecreaseProgesterone on hCG administration day
    Study

    n: not reported in source

    Comparator
    Recombinant FSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    As expected, the mean value of luteinizing hormone and progesterone, on the day of human chorionic gonadotropin administration were statistically significantly lower in patients receiving GnRH antagonist than the control group (p = 0.002).
    2 context sentences
    Summary · context
    A total of 175 intrauterine insemination (IUI) cycles in women with polycystic ovary syndrome (PCOS) were included in the study.
    Summary · context
    Women in the control group (n = 87) underwent controlled ovarian stimulation (COS) with recombinant follicle stimulating hormone (r-FSH) only, while women in the study group (n = 88) were administered r-FSH plus cetrorelix.
  3. 03HumanNon-randomized trialEfficacy outcome

    In women with PCOS undergoing IUI, premature luteinization was less frequent with added cetrorelix than recombinant FSH alone.

    In plain wordsIn women with PCOS undergoing IUI, premature luteinization was less frequent with added cetrorelix than recombinant FSH alone.

    Peptide
    Cetrorelix
    Outcome
    DecreasePremature luteinization
    Study

    n: not reported in source

    Comparator
    Recombinant FSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Premature luteinization
    1.1%
    cetrorelix
    Premature luteinization
    17.2%
    control
    P value
    0.001
    between groups

    Source sentences

    Summary
    Premature luteinization occurred in only one of the patients in the GnRH antagonist group (1.1%) and in 15 of the 88 cycles in the control group (17.2%), showing a significant difference between the two groups (P = 0.001).
    2 context sentences
    Summary · context
    A total of 175 intrauterine insemination (IUI) cycles in women with polycystic ovary syndrome (PCOS) were included in the study.
    Summary · context
    Women in the control group (n = 87) underwent controlled ovarian stimulation (COS) with recombinant follicle stimulating hormone (r-FSH) only, while women in the study group (n = 88) were administered r-FSH plus cetrorelix.
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with PCOS undergoing IUI, clinical pregnancy rates did not differ significantly between added cetrorelix and recombinant FSH alone.

    In plain wordsIn women with PCOS undergoing IUI, pregnancy rates did not differ significantly between added cetrorelix and recombinant FSH alone.

    Peptide
    Cetrorelix
    Outcome
    No significant changeClinical pregnancy per cycle
    Study

    n: not reported in source

    Comparator
    Recombinant FSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Clinical pregnancy
    25%
    cetrorelix
    Clinical pregnancy
    14.9%
    control
    P value
    0.096
    between groups

    Source sentences

    Summary
    The clinical pregnancy rate per cycle was higher in GnRH-antagonist group compared to the control group but the difference did not reach to a statistical significance (25% vs 14.9%, P = 0.096).
    2 context sentences
    Summary · context
    A total of 175 intrauterine insemination (IUI) cycles in women with polycystic ovary syndrome (PCOS) were included in the study.
    Summary · context
    Women in the control group (n = 87) underwent controlled ovarian stimulation (COS) with recombinant follicle stimulating hormone (r-FSH) only, while women in the study group (n = 88) were administered r-FSH plus cetrorelix.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.